<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29293">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02725372</url>
  </required_header>
  <id_info>
    <org_study_id>PULSE-PAH-004</org_study_id>
    <nct_id>NCT02725372</nct_id>
  </id_info>
  <brief_title>Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH</brief_title>
  <acronym>INOvation-1</acronym>
  <official_title>A Phase 3, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellerophon Pulse Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellerophon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety,
      tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in
      symptomatic subjects with pulmonary arterial hypertension (PAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3, placebo controlled, double-blind, randomized, clinical study to determine safety,
      tolerability and efficacy of pulsed inhaled nitric oxide (iNO) versus placebo as add-on
      therapy in subjects with pulmonary arterial hypertension (PAH) who remain symptomatic on
      approved PAH monotherapy or combination approved PAH therapy and long term oxygen therapy
      (LTOT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Six Minute Walk Distance (6MWD) - Change from baseline 6MWD at 18 Weeks</measure>
    <time_frame>Baseline, 18 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Worsening (TTCW)</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>The time (in days) from start of treatment to first event (first day the event is noted), measured from baseline to end of study. TTCW event is defined as any of the following:
Death (all-cause mortality)
Atrial septostomy
Hospitalization due to worsening of PAH (adjudicated)
Start of new specific PAH treatment (endothelin receptor antagonists [ERAs], phosphodiesterase type-5 [PDE-5] inhibitors or prostanoids), an increase in the dose of an ERA or PDE-5, increase in the dose or frequency of an inhaled prostanoids, or an increase in the dose of an intravenous or subcutaneous prostanoids by &gt;10%.
Decrease of &gt;15% from baseline or &gt;30% compared with the last study related measurement in 6MWD should be confirmed by a repeat measurement performed at least 14 days later
Worsening of WHO Functional Class (e.g., from Class II to Class III or IV, OR Class III to Class IV); and should be confirmed by a repeat assessment at least 14 days later</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in World Health Organization (WHO) Functional Class</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in health-related quality of life using Short Form-36 (SF-36) version 2 health survey</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cardiac output (CO) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in cardiac index (CI) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pulmonary artery pressure (mPAP) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pulmonary capillary wedge pressure (mPCWP) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in systolic pulmonary artery pressure (sPAP) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in diastolic pulmonary artery pressure (dPAP) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in pulmonary vascular resistance (PVR) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in oxygen saturation by pulse oximeter (SpO2) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in mixed venous O2 measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in right atrial pressure (RAP) measured by Right Heart Catheterization (RHC) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of right ventricular fractional area in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of right ventricular systolic pulmonary artery pressure (sPAP) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of right ventricular tricuspid annular motion/tricuspid annular plane systolic excursion in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of right ventricular tricuspid annular systolic velocity in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of right ventricular Tei index in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of left ventricular ejection fraction (LVEF) in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of left ventricular size in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in echocardiogram measurements of improvement in LV early diastolic relaxation velocity in a subset of subjects at selected sites</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>Screening, Week 18</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Borg dyspnea score immediately following Six Minute Walk Test (6MWT)</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Six Minute Walk Distance (6MWD) as related to degree of drug adherence</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with unsatisfactory clinical response</measure>
    <time_frame>Baseline, Week 2, Week 6, Week 10, Week 14, Week 18</time_frame>
    <description>Defined as WHO Functional Class III or IV symptoms with no improvement in 6MWD</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects undergoing heart-lung or lung transplantation, number of subjects listed for transplantation, and deaths while waiting transplantation</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Medical healthcare resource utilization questionnaire</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>At screening, subjects will be asked about the number of hospitalizations, ER visits, and outpatient visits in the previous year. At each visit thereafter, the subject's medical healthcare resource utilization in terms of number of hospitalizations and outpatient medical care, including ER visits, since the previous visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of device malfunction and/or device failure leading to an Adverse Event</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of rebound pulmonary hypertension</measure>
    <time_frame>Baseline, Week 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically significant changes in clinical laboratory tests, pulmonary function tests, vital signs</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitrix Oxide for inhalation in Size 0.074 liter aluminum cartridges at a concentration of 6.0 mg/L (4880 ppm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Size 0.074 liter aluminum cartridges containing Nitrogen (N2, 99.999%) gas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iNO 15 mcg/kg IBW/hr</intervention_name>
    <description>Run-In Period (Week 0 to Week 2)</description>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
    <other_name>Inhaled Nitric Oxide</other_name>
    <other_name>iNO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iNO 75 mcg/kg IBW/hr</intervention_name>
    <description>Treatment Period (Week 3 to Week 18/End of Study)</description>
    <arm_group_label>Inhaled Nitric Oxide (iNO)</arm_group_label>
    <other_name>Inhaled Nitric Oxide</other_name>
    <other_name>iNO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dose setting of 15 mcg/kg IBW/hr</intervention_name>
    <description>Run-In Period (Week 0 to Week 2)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Dose setting of 75 mcg/kg IBW/hr</intervention_name>
    <description>Treatment Period (Week 3 to Week 18/End of Study)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Informed Consent Form (and assent as appropriate) prior to the initiation of
             any study mandated procedures or assessments

          2. A confirmed diagnosis of PAH Group 1 who have either idiopathic PAH (IPAH), heritable
             PAH, drug and toxin-induced PAH, associated PAH (APAH) with connective tissue disease
             (CTD), APAH with repaired simple congenital systemic to pulmonary shunt (i.e., atrial
             septal defect, ventricular septal defect and/or patent ductus arteriosus; complete
             repair at least 1 year prior to Screening), APAH with human immunodeficiency virus
             (HIV), or APAH with portal hypertension

          3. Subjects receiving at least one PAH specific therapy (ERA or PDE-5 inhibitor, or
             inhaled, subcutaneous, or intravenous prostacyclin or a prostacyclin analog) with the
             same type of therapy for at least 3 months with stable dosing 4 weeks prior to
             Screening. (Subjects should be receiving optimal therapy according to the disease
             severity)

          4. Subjects using oxygen therapy by nasal cannula for at least 4 weeks prior to
             Screening

          5. PAH diagnosis confirmed by RHC within the previous 5 years, according to the
             following definitions:

               -  PVR ≥ 400 dynes.sec.cm-5 (5 Wood units)

               -  mPAP ≥ 25 mmHg

               -  PCWP or LVEDP ≤ 15 mmHg

               -  Subjects who otherwise meet all the inclusion criteria and none of the exclusion
                  criteria but have not undergone a RHC within the previous 5 years may be
                  considered eligible for the study if they undergo a RHC and then meet the
                  pulmonary hemodynamics criterion

          6. 6MWD ≥ 100 meters and ≤ 450 meters prior to randomization

          7. WHO Functional Class II-IV. Subjects with WHO Functional Class IV should be treated
             with prostacyclin or a prostacyclin analog (subcutaneous or intravenous), plus at
             least one additional PAH specific therapy (ERA or PDE-5), if available to the subject
             and reimbursed by health insurance

          8. Age between 18 and 80 years (inclusive)

          9. Willingness to use INOpulse delivery device for at least 16 hours per day

         10. Willingness to continue on study drug until last subject has completed Week 18
             assessments (EOS)

         11. Female subjects of childbearing potential must have a negative pre-treatment
             pregnancy test (serum or urine). All female subjects should take adequate precaution
             to avoid pregnancy.

        Exclusion Criteria:

          1. Subjects with known HIV infection who have a history within the past 3 months of any
             opportunistic pulmonary disease (e.g., tuberculosis, Pneumocystis carinii pneumonia,
             or other pneumonias) at the time of Screening

          2. PAH associated with untreated thyroid disorders, glycogen storage disease, Gaucher's
             disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies,
             myeloproliferative disorders or splenectomy

          3. Subjects with pulmonary conditions that may contribute to PAH including, but not
             limited to, chronic bronchiectasis, cystic fibrosis, or other pulmonary condition
             that the Investigator may deem to contribute to the severity of the disease or impair
             the delivery of iNO due to airway disease

          4. Subjects receiving riociguat

          5. Subjects receiving oral prostanoids as monotherapy

          6. Any subject with unrepaired congenital heart disease or repaired congenital heart
             disease other than the simple congenital to systemic shunts specified in the
             inclusion criteria, i.e., PAH associated with non-corrected simple congenital
             systemic-to-pulmonary shunts, corrected simple congenital systemic-to-pulmonary shunt
             with residual shunt post repair, or complex systemic-to-pulmonary shunts, corrected
             or non-corrected, or any other complex congenital heart disease, corrected or
             non-corrected

          7. PAH associated with significant venous or capillary involvement, known or suspected
             pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis

          8. Any subject with WHO PH Groups 2, 3, 4 or 5

          9. Subjects with any of the following cardiac abnormalities:

               1. Underlying cardiomyopathy or aortic or mitral valve disease

               2. Left ventricular systolic dysfunction (LVSD), i.e., left ventricular ejection
                  fraction (LVEF) &lt; 40% or left ventricular shortening fraction (LVSF) &lt; 22%, as
                  determined by local reading

               3. Current symptomatic coronary artery disease, myocardial infarction within 1
                  year, or any coronary artery interventions within 6 months

         10. Systemic hypertension defined as systolic blood pressure (SBP) &gt; 160 mmHg and/or
             diastolic blood pressure (DBP) &gt; 100 mmHg persistent at Screening after a period of
             rest (treated or untreated)

         11. Subjects with a history of deep vein thrombosis, pulmonary embolism/infarction or
             prothrombotic disorder must have had chronic thromboembolic pulmonary hypertension
             (CTEPH) excluded by ventilation/perfusion lung (V/Q) scan

         12. Moderate to severe obstructive lung disease defined as both a forced expiratory
             volume in 1 second/forced vital capacity (FEV1/FVC) &lt; 70% and FEV1 &lt; 65% of predicted
             value

         13. Moderate to severe restrictive lung disease: total lung capacity (TLC) &lt; 60% of
             predicted; if TLC 60% to 70% predicted, a high resolution CT scan showing diffuse
             disease or more than mild patchy disease

         14. Any subject who develops or has developed a PCWP &gt; 20 mmHg during acute vasodilator
             testing (AVT)

         15. Systemic hypotension defined as SBP &lt; 90 mmHg persistent at Screening after a period
             of rest

         16. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C

         17. On dialysis

         18. Acute or chronic physical impairment (other than dyspnea due to PAH) that would limit
             the ability to comply with study procedures or adherence to therapy (i.e., 6MWT),
             including carrying and wearing the pulsed delivery device per study protocol, or
             medical problem(s) likely to preclude completion of the study

         19. Pregnant or breastfeeding females at Screening

         20. Administered L-arginine within 1 month prior to Screening

         21. Known concomitant life-threatening disease with a life expectancy less than 1 year

         22. Atrial septostomy within 3 months preceding randomization

         23. Any subject who requires the use of a continuous positive airway pressure (CPAP),
             bilevel positive airway pressure (BiPAP), or any other positive pressure devices

         24. Use of investigational drugs or devices within 1 month prior to Screening (other than
             acute vasodilator testing with iNO)

         25. Any underlying medical or psychiatric condition that, in the opinion of the
             Investigator, makes the subject an unsuitable candidate for the study

         26. Any subject who has been enrolled in any previous clinical study with inhaled NO
             administered through pulse delivery.

        Additional Criteria to Continue to Treatment Phase from Run-in Period (Week 0 to Week 2):

          1. Subjects must demonstrate an average daily usage of the INOpulse device of ≥ 16 hours
             (rounded to the nearest hour) with no more than 2 days of usage &lt; 8 hours per day,
             during the initial 2 weeks of study.

          2. If a subject experiences clinical worsening during the Screening or Run-in period,
             the subject will not be eligible to enter into the treatment phase of the study.

          3. Subjects who have been randomized at baseline and found not to meet all Inclusion
             criteria and/or who meet Exclusion criteria during the Run-in period will be
             withdrawn from the study. Additional subjects will be enrolled to meet total target
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deborah Quinn, MD</last_name>
    <email>deborah.quinn@bellerophon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alyssa Opresnick</last_name>
    <email>alyssa.opresnick@bellerophon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, Ltd</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pulmonary Disease Specialists, PA</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-5727</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Himanshu Chandarana, MD, PA</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 17, 2016</lastchanged_date>
  <firstreceived_date>January 19, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>Inhaled Nitric Oxide</keyword>
  <keyword>iNO</keyword>
  <keyword>long term oxygen therapy</keyword>
  <keyword>oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
